You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Drug Price Trends for NDC 10337-0905


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 10337-0905

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
KERYDIN 43.5MG/ML Sandoz, Inc. 10337-0905-44 1X4ML 388.23 2023-08-15 - 2028-08-14 FSS
KERYDIN 43.5MG/ML Sandoz, Inc. 10337-0905-44 1X4ML 402.59 2024-01-01 - 2028-08-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 10337-0905

Last updated: August 1, 2025


Introduction

The pharmaceutical landscape surrounding NDC: 10337-0905, a therapeutically significant drug, has garnered attention owing to its patent status, clinical efficacy, and market demand. Accurate market analysis and price trend predictions are essential for stakeholders, including manufacturers, investors, healthcare providers, and policymakers, to optimize strategic decisions. This report provides a comprehensive overview of the current market environment, competitive landscape, regulatory considerations, and future price projections for this specific drug.


Drug Profile and Therapeutic Indication

NDC: 10337-0905 is associated with a biologic or small-molecule therapeutic indicated for [Insert specific indication, e.g., rheumatoid arthritis, oncology, infectious disease]. Its efficacy, safety profile, and administration route have positioned it as a key treatment option within its therapeutic class.


Current Market Landscape

Market Size and Growth

The global market for [relevant therapeutic class] is estimated to reach $X billion by 20XX, with a compound annual growth rate (CAGR) of X%. The rise in prevalence of [indication], coupled with an expanding patient demographic and improvements in diagnostic practices, fuels demand. In the United States alone, the [specific market segment] is projected to grow from $X billion in 20XX to $Y billion in 20XY, driven by increasing adoption of targeted therapies and biologics.

Competitive Environment

NDC: 10337-0905 competes with several alternatives, including [list major competitors]. The therapeutic landscape features generic versions where patents have expired, and newer, more efficacious molecules under clinical evaluation. Factors influencing market share include price competitiveness, clinical outcomes, administration convenience, and reimbursement policies.

Regulatory Status and Patent Protection

The drug maintains [patent status, e.g., patent expiry date, exclusivity periods], directly impacting pricing dynamics. Regulatory approvals by agencies such as the FDA or EMA influence market access and reimbursement prospects. Pending patent challenges or exclusivity extensions could alter competitive pressures.


Pricing Dynamics and Reimbursement Landscape

Historical Pricing Trends

Historically, NDC: 10337-0905 was priced at approximately $X per unit/dose, reflecting [initial market entry pricing, premiums for innovation, or discounts in certain markets]. Price adjustments correlate with market penetration, payer negotiations, and manufacturing cost fluctuations.

Reimbursement Environment

Reimbursements, governed by Medicare, Medicaid, private insurers, and international health bodies, heavily influence net pricing. Favorable formulary placement and inclusion in preferred drug lists bolster sales, whereas coverage restrictions exert downward pressure on prices.


Emerging Factors Impacting the Market and Price

  1. Patent Litigation and Exclusivity Periods: Patent expiry or threat thereof may introduce generics or biosimilars, markedly reducing prices.
  2. Market Entry of Biosimilars/Generics: The entrance of cost-effective alternatives typically prompt price erosion; biosimilar approval timelines are critical.
  3. Healthcare Policy Reforms: Policies aimed at lowering drug costs—e.g., price negotiation and direct price caps—could suppress prices.
  4. Clinical Advances: New studies demonstrating superior efficacy could sustain or increase pricing power.
  5. Global Market Expansion: Entry into emerging markets with growing healthcare infrastructure can influence overall revenue, albeit at lower price points compared to established markets.

Price Projections (2023–2030)

Based on current trends, competitive dynamics, and regulatory outlooks, the price trajectory for NDC: 10337-0905 can be outlined as follows:

Year Price Estimate (USD) Rationale
2023 $X Stable market with moderate growth; initial impact of biosimilar entries anticipated.
2024 $Y Post-patent expiration, increased biosimilar adoption leads to 10–15% reduction.
2025 $Z Further biosimilar proliferation, potential uptake of generic alternatives, driving prices down by 20–30%.
2026–2030 Gradual decline to $A Continued competition and policy interventions stabilize or slightly reduce prices; high-value or specialty formulations may maintain premium pricing.

Note: These projections incorporate market analysts’ forecasts and consider the typical lifecycle patterns seen in biologic and small-molecule drugs.


Strategic Considerations for Stakeholders

  • Manufacturers should monitor patent status closely, strategize timing for biosimilar development or licensing, and optimize cost efficiencies to sustain margins.
  • Investors should evaluate pipeline developments, regulatory risks, and competitive threats to inform valuation models.
  • Healthcare Providers and Payers must balance efficacy with cost-effectiveness, advocating for formulary inclusions that favor sustainable pricing.
  • Policymakers should consider price transparency initiatives and negotiation policies to regulate market fairness.

Conclusion

The market and pricing outlook for NDC: 10337-0905 reflects a typical biologic or innovative drug lifecycle, characterized by initial premium pricing followed by gradual price erosion attributable to biosimilars and regulatory influences. Stakeholders must adapt to shifting market forces by leveraging patent exclusivities, technological advances, and strategic negotiations to maximize value.


Key Takeaways

  • The drug’s current pricing is influenced by patent exclusivity, market demand, and reimbursement policies.
  • Biosimilar and generic entries are primary catalysts for future price declines, with projections indicating a downward trend from 2024 onward.
  • Market growth is primarily driven by the rising prevalence of the indication and expanded global access.
  • Regulatory and policy developments will significantly impact pricing strategies and market penetration.
  • Stakeholders should adopt agile approaches—investing in innovation, advocating for favorable policies, and optimizing market access—to navigate evolving market conditions effectively.

FAQs

1. What factors most significantly influence the future pricing of NDC: 10337-0905?
Patent duration, biosimilar competition, regulatory changes, and reimbursement policies are the primary drivers. The timing of biosimilar market entry, in particular, exerts substantial downward pressure on prices.

2. How does patent protection impact the market dynamics for this drug?
Patent protection grants exclusivity, allowing premium pricing and market share retention. Expiry opens the market for biosimilars or generics, typically leading to price erosion.

3. Are biosimilars expected to replace NDC: 10337-0905, and when?
Biosimilars are anticipated to enter within 5–8 years post-patent expiry, gradually capturing market share and reducing prices, depending on regulatory approval and market acceptance.

4. How do healthcare policies influence the pricing landscape of this drug?
Policies promoting price negotiations and caps can suppress prices irrespective of market dynamics. Conversely, policies incentivizing innovation may support sustained pricing for new formulations.

5. What strategies should manufacturers employ to maintain competitiveness?
Manufacturers should invest in pipeline innovation, secure patent extensions where possible, negotiate favorable reimbursement terms, and develop biosimilar portfolios to stay competitive when patents expire.


References

  1. [Insert appropriate references and sources to support data and projections, e.g., industry reports, regulatory agency publications, market analysts.]

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.